Having trouble accessing articles? Reset your cache.

Roche submits obinutuzumab applications

Roche (SIX:ROG; OTCQX:RHHBY) and its Genentech Inc. unit submitted regulatory applications to FDA and EMA for obinutuzumab ( GA101) to

Read the full 200 word article

User Sign In

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE